After adding several new businesses and products through acquisitions over the last couple of years, Invitrogen is now considering selling off or discontinuing some 'minor' yet undisclosed product lines or business units, the firm said this week.

The firm is not disclosing which products or businesses are being considered for divestiture, and a company spokesperson told BioCommerce Week that the process is the natural result of integrating many pieces into the company over the past two years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.